Active Ingredient in HyBryteTM for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis PRINCETON, N.J. , Oct.
22, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX ) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin". The newly issued patent's claims are directed to a novel, highly purified form of synthetic hypericin manufactured through a unique proprietary process.
Synthetic hypericin is the active pharmaceutical ingredient in HyBryteTM , the Company's photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL), set to initiate a confirmatory Phase 3 clinical trial before the end of the year. The same active ingredient is also used in SGX302, a potential topical treatment for plaque psoriasis. This new granted patent (HK1260757) is a related patent to US Pat.
Nos. 10,053,413 and 10,526,268, previously issued in the United States (U.S.
), and is in the same family as another patent granted in Europe . These patents are expected to expire in 2036, and form part of a larger collection of different patent families, including previously granted foreign patents covering liquid formulations and methods of use (EP Pat. No.
2,571,507) and issued U.S. patents for methods of s.
